Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simple Bile Acid Blood Test Predicts Stillbirth Risk

By LabMedica International staff writers
Posted on 25 Feb 2019
Intrahepatic cholestasis of pregnancy (ICP) is caused by a build-up of bile acids in the blood, and symptoms include pruritus. ICP is a liver disorder affecting approximately 5,300 pregnancies annually in the UK, more than 14 every day.

ICP is diagnosed in women with gestational pruritus and increased serum bile acids, and can be complicated by preterm labor, fetal asphyxia, meconium-stained amniotic fluid, and stillbirth. It was previously thought that small increases in bile acid concentration are associated with higher risks of stillbirth. Pregnant women showing symptoms of ICP, therefore, are often offered early induction of labor at around 37 weeks in order to prevent stillbirth.

A large team of international scientists collaborating with Kings College London (London, UK) analyzed more than 170,000 pregnancies from 40 international studies to understand the link between ICP, bile acid levels and stillbirth. The results of the study show that for the majority of women with ICP, who have bile acid concentration below 100 μmol/, the risk of stillbirth is not significantly greater than that of pregnant women without ICP. This means they need no further treatment other than regular bile acid blood tests for the remainder of their pregnancy.

The scientists reported that stillbirth occurred in 45/4,936 (0.83%) of intrahepatic cholestasis of pregnancy cases and 519/163,947 (0.32%) of control pregnancies (odds ratio [OR] 1.46). In singleton pregnancies, stillbirth was associated with maximum total bile acid concentration (area under the receiver operating characteristic curve [ROC AUC] 0.83), but not alanine aminotransferase (ROC AUC 0·46). For singleton pregnancies, the prevalence of stillbirth was 3/2,310 (0.13%) of intrahepatic cholestasis of pregnancy cases in women with serum total bile acids of less than 40 μmol/L versus 4/1,412 (0.28%) of cases with total bile acids of 40–99 μmol/L (hazard ratio [HR] 2.35), and versus 18/524 (3.44%) of cases for bile acids of 100 μmol/L or more (HR 30.5).

Caroline Ovadia, BCh, a Clinical Lecturer and first author of the study, said, “This marks a real step forward in the diagnosis and management of liver disorders during pregnancy. Being able to measure the risks to women and their babies by simple tests allows doctors to concentrate treatment on those who really need it. It also means that women will not have to be offered preterm birth unnecessarily which comes with associated risks to their babies including admission to neonatal units, breathing problems and jaundice.” The study was published on February 14, 2019, in the journal The Lancet.

Related Links:
Kings College London


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.